Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Getting a Handle on Lymphopenia With Tecfidera
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas.
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes.
Central fatigue in multiple sclerosis: a review of the literature.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Multiple sclerosis: A lifestyle disease?
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Emerging oral agents for multiple sclerosis.
The impact of multiple sclerosis relapse treatment on migration of effector T cells - Preliminary study.
A Unified Frequency Domain Model to Study the Effect of Demyelination on Axonal Conduction.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Ethnicity and prevalence of multiple sclerosis in east London.
EU regulator warns on possible MS drugs side effects
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.

Pages